User:Shawndouglas/Sandbox - Revision history

Shawndouglas: Replaced content with "
TOC
{{ombox | type = notice | style = width: 960px; | text = This is my primary sandbox page, where I play with features and..."

2022-02-01T17:47:40Z

Replaced content with "<div class="nonumtoc">__TOC__</div> {{ombox | type = notice | style = width: 960px; | text = This is my primary sandbox page, where I play with features and..."

Show changes

Shawndouglas at 20:21, 24 September 2021

2021-09-24T20:21:16Z

← Older revision		Revision as of 20:21, 24 September 2021
Line 89:		Line 89:
	<!--		<!--
	===CannaQA===		===CannaQA===
	CannaQA LIMS is cloud-based LIMS software designed specifically for the cannabis testing industry, with certificates of analysis, track-and-trace support, "and other aspects of data management required for successful, cost-effective operation in today's highly competitive and fast-growing cannabis testing market."<ref name="LLXLIMSFor19">{{cite web \|url=https://www.cannaqa.com/blog/lims-for-cannabis-testing/ \|title=LIMS for Cannabis Testing ... It's all about delivering quality information \|work=CannaQA \|publisher=LabLynx, Inc \|date=18 July 2019 \|accessdate=02 March 2020}}</ref> -->		CannaQA LIMS is cloud-based LIMS software designed specifically for the cannabis testing industry, with certificates of analysis, track-and-trace support, "and other aspects of data management required for successful, cost-effective operation in today's highly competitive and fast-growing cannabis testing market."<ref name="LLXLIMSFor19">{{cite web \|url=https://www.cannaqa.com/blog/lims-for-cannabis-testing/ \|title=LIMS for Cannabis Testing ... It's all about delivering quality information \|work=CannaQA \|publisher=LabLynx, Inc \|date=18 July 2019 \|accessdate=02 March 2020}}</ref>

			===LabDrive===
			LabDrive is "a secure file and data management productivity suite." Little else is said about the offering.<ref name="LLLXAddOns">{{cite web \|url=https://www.lablynx.com/add-on-solutions/ \|title=LIMS Add-On Solutions \|publisher=LabLynx, Inc \|accessdate=24 September 2021}}</ref>
			-->

	===LabVia===		===LabVia===

Shawndouglas at 17:18, 24 September 2021

2021-09-24T17:18:31Z

← Older revision		Revision as of 17:18, 24 September 2021
Line 86:		Line 86:
	==Technology and products==		==Technology and products==
	===ELab===		===ELab===
	ELab is a hosted [[software as a service]] (SaaS) [[laboratory information management system]] (LIMS) + [[laboratory information system]] (LIS). Introduced in 2009 as webLIMS<ref name="webLIMS1" />, ELab "~~offers complete functionality for~~ every ~~type of~~ lab ~~- at a price that's affordable~~."<ref name="ELabLimsNew">{{cite web \|url=https://www.lablynx.com/~~weblims~~/ \|title=~~Laboratory Management System (~~LIMS~~/LIS/LES)~~ \|publisher=LabLynx, Inc \|accessdate=~~26 January 2018~~}}</ref> The software can be hosted in the cloud or self-hosted. In April 2020, a COVID-19 testing module was developed for ELab that extends its molecular diagnostics and other related COVID-19 workflows.<ref name="PRNLabLynx20" /><ref name="LLXCovidElab">{{cite web \|url=https://www.covidlims.com/elab-lims/ \|title=ELab: The LiMS and Database at The Core of Lablynx’s COVIDLiMS Solution \|publisher=LabLynx, Inc \|accessdate=20 October 2020}}</ref>		ELab is a hosted [[software as a service]] (SaaS) [[laboratory information management system]] (LIMS) + [[laboratory information system]] (LIS). Introduced in 2009 as webLIMS<ref name="webLIMS1" />, ELab is "designed ... to adapt to every lab’s unique needs with the flexibility to grow with your lab as you expand to meet your business goals."<ref name="ELabLimsNew">{{cite web \|url=https://www.lablynx.com/lims/ \|title=LabLynx ELab LIMS \|publisher=LabLynx, Inc \|accessdate=24 September 2021}}</ref> The software can be hosted in the cloud or self-hosted. In April 2020, a COVID-19 testing module was developed for ELab that extends its molecular diagnostics and other related COVID-19 workflows.<ref name="PRNLabLynx20" /><ref name="LLXCovidElab">{{cite web \|url=https://www.covidlims.com/elab-lims/ \|title=ELab: The LiMS and Database at The Core of Lablynx’s COVIDLiMS Solution \|publisher=LabLynx, Inc \|accessdate=20 October 2020}}</ref>
	<!--		<!--
	===CannaQA===		===CannaQA===
Line 101:		Line 101:
	{\| class="wikitable collapsible" style="border-style:none;" background="#ffffff" border="0" cellpadding="0" cellspacing="0"		{\| class="wikitable collapsible" style="border-style:none;" background="#ffffff" border="0" cellpadding="0" cellspacing="0"
	\|-		\|-
	! colspan="2"\| Product: [https://www.lablynx.com/~~weblims~~/ ELab]		! colspan="2"\| Product: [https://www.lablynx.com/lims/ ELab]
	\|-		\|-
	\| style="background-color:white; border-style:none;"\| {{Databox LIMSfeature		\| style="background-color:white; border-style:none;"\| {{Databox LIMSfeature
Line 108:		Line 108:
	\| sample_batch = Y<ref name="ELabLimsNew" />		\| sample_batch = Y<ref name="ELabLimsNew" />
	\| task_event_sched = Y<ref name="ELabLimsNew" />		\| task_event_sched = Y<ref name="ELabLimsNew" />
	\| manual_entry = ~~Y<ref name="ELabLimsNew" />~~		\| manual_entry =
	\| multiple_view = Y<ref name="ELabLimsNew" />		\| multiple_view = Y<ref name="ELabLimsNew" />
	\| data_analysis = ~~Y<ref name="ELabLimsNew" />~~		\| data_analysis =
	\| data_sharing = ~~Y<ref name="ELabLimsNew" />~~		\| data_sharing =
	\| custom_fields = Y<ref name="ELabLimsNew" />		\| custom_fields = Y<ref name="ELabLimsNew" />
	\| query = ~~Y<ref name="ELabLimsNew" />~~		\| query =
	\| import_data = ~~Y<ref name="ELabLimsNew" />~~		\| import_data =
	\| data_linking_int = Y<ref name="ELabLimsNew" />		\| data_linking_int = Y<ref name="ELabLimsNew" />
	\| data_linking_ext = ~~Y<ref name="ELabLimsNew" />~~		\| data_linking_ext =
	\| eln_support = ~~Y<ref name="ELabLimsNew" />~~		\| eln_support =
	\| export_msexcel = ~~Y<ref name="ELabLimsNew" />~~		\| export_msexcel =
	\| export_raw = ~~Y<ref name="ELabLimsNew" />~~		\| export_raw =
	\| data_warehouse = ~~Y<ref name="ELabLimsNew" />~~		\| data_warehouse =
	\| deadline_control = ~~Y<ref name="ELabLimsNew" />~~		\| deadline_control =
	\| production_control = Y<ref name="ELabLimsNew" />		\| production_control = Y<ref name="ELabLimsNew" />
	\| project_task_man = Y<ref name="ELabLimsNew" />		\| project_task_man = Y<ref name="ELabLimsNew" />
	\| inventory_man = Y<ref name="ELabLimsNew" />		\| inventory_man = Y<ref name="ELabLimsNew" />
	\| document_man = Y<ref name="ELabLimsNew" />		\| document_man = Y<ref name="ELabLimsNew" />
	\| case_man = ~~Y<ref name="ELabLimsNew" />~~		\| case_man =
	\| workflow_man = ~~Y<ref name="ELabLimsNew" />~~		\| workflow_man =
	\| spec_man = ~~Y<ref name="ELabLimsNew" />~~		\| spec_man =
	\| customer_man = ~~Y<ref name="ELabLimsNew" />~~		\| customer_man =
	\| billing_man = Y<ref name="ELabLimsNew" />		\| billing_man = Y<ref name="ELabLimsNew" />

	\| reg_compliance = Y<ref name="ELabLimsNew" />		\| reg_compliance = Y<ref name="ELabLimsNew" />
	\| qa_qc = ~~Y<ref name="ELabLimsNew" />~~		\| qa_qc =
	\| performance_eval = ~~Y<ref name="ELabLimsNew" />~~		\| performance_eval =
	\| audit_trail = ~~Y<ref name="ELabLimsNew" />~~		\| audit_trail =
	\| chain_custody = Y<ref name="ELabLimsNew" />		\| chain_custody = Y<ref name="ELabLimsNew" />
	\| roles_security = ~~Y<ref name="ELabLimsNew" />~~		\| roles_security =
	\| data_norm = ~~Y<ref name="ELabLimsNew" />~~		\| data_norm =
	\| data_val = ~~Y<ref name="ELabLimsNew" />~~		\| data_val =
	\| data_encrypt = ~~Y<ref name="ELabLimsNew" />~~		\| data_encrypt =
	\| version_control = ~~Y<ref name="ELabLimsNew" />~~		\| version_control =
	\| data_backup = ~~Y<ref name="ELabLimsNew" />~~		\| data_backup =
	\| enviro_monitoring = ~~Y<ref name="ELabLimsNew" />~~		\| enviro_monitoring =

	\| custom_reporting = Y<ref name="ELabLimsNew" />		\| custom_reporting = Y<ref name="ELabLimsNew" />
	\| report_printing = ~~Y<ref name="ELabLimsNew" />~~		\| report_printing =
	\| label_support = Y<ref name="ELabLimsNew" />		\| label_support = Y<ref name="ELabLimsNew" />
	\| barcode_support = Y<ref name="ELabLimsNew" />		\| barcode_support = Y<ref name="ELabLimsNew" />
	\| export_pdf = ~~Y<ref name="ELabLimsNew" />~~		\| export_pdf =
	\| export_msword = ~~Y<ref name="ELabLimsNew" />~~		\| export_msword =
	\| export_htmlxml = ~~Y<ref name="ELabLimsNew" />~~		\| export_htmlxml =
	\| fax_integration = ~~Y<ref name="ELabLimsNew" />~~		\| fax_integration =
	\| email_integration = ~~Y<ref name="ELabLimsNew" />~~		\| email_integration =

	\| admin_manage = Y<ref name="ELabLimsNew" />		\| admin_manage = Y<ref name="ELabLimsNew" />
	\| modular =		\| modular =
	\| instrument_inter = ~~Y<ref name="ELabLimsNew" />~~		\| instrument_inter =
	\| mobile_device = ~~Y<ref name="ELabLimsNew" />~~		\| mobile_device =
	\| alarms_alerts = Y<ref name="ELabLimsNew" />		\| alarms_alerts = Y<ref name="ELabLimsNew" />
	\| work_timetrack = ~~Y<ref name="ELabLimsNew" />~~		\| work_timetrack =
	\| voice_rec =		\| voice_rec =
	\| external_monitor = Y<ref name="ELabLimsNew" />		\| external_monitor = Y<ref name="ELabLimsNew" />
	\| messaging = ~~Y<ref name="ELabLimsNew" />~~		\| messaging =
	\| multilingual = Y<ref name="ELabLimsNew" />		\| multilingual = Y<ref name="ELabLimsNew" />
	\| network = ~~Y<ref name="ELabLimsNew" />~~		\| network =
	\| web_client = ~~Y<ref name="ELabLimsNew" />~~		\| web_client =
	\| online_help = ~~Y<ref name="ELabLimsNew" />~~		\| online_help =
	\| saas_model = ~~Y<ref name="ELabLimsNew" />~~		\| saas_model =
	\| usage_cost =		\| usage_cost =

Line 257:		Line 257:
	===Pricing===		===Pricing===
	====ELab====		====ELab====
	Source for pricing information is directly from LabLynx. Additional pricing information can be gleaned from [https://www.gsaadvantage.gov/ref_text/GS35F511DA/~~0R3HDC~~.~~3GGC22_GS~~-35F-~~511DA_IFSS600LABLYNX~~.PDF GSA Avantage]. As prices may change at any time, always contact the vendor directly to obtain a price list or quote.		Source for pricing information is directly from LabLynx. Additional pricing information can be gleaned from [https://www.gsaadvantage.gov/ref_text/GS35F511DA/0VZ7MY.3RPKLP_GS-35F-511DA_GS35F511DAIFSS600LABLYNX.PDF GSA Avantage]. As prices may change at any time, always contact the vendor directly to obtain a price list or quote.

	{\|		{\|
Line 431:		Line 431:
	* [https://www.limsforum.com/ LIMSforum community portal]		* [https://www.limsforum.com/ LIMSforum community portal]
	* [https://www.limswiki.org/ LIMSwiki site]		* [https://www.limswiki.org/ LIMSwiki site]
			* [https://www.cannaqa.wiki/ CannaQAwiki site]
	* [https://vimeo.com/lablynx LabLynx on Vimeo]		* [https://vimeo.com/lablynx LabLynx on Vimeo]
	* [https://www.youtube.com/user/lablynx LabLynx on YouTube]		* [https://www.youtube.com/user/lablynx LabLynx on YouTube]

Shawndouglas at 16:57, 24 September 2021

2021-09-24T16:57:28Z

← Older revision		Revision as of 16:57, 24 September 2021
Line 63:		Line 63:
	By July 2000, the LabLynx division of ASC separated to become its own incorporated entity.<ref name="SoS_llx" /> And while ASC eventually ceased to exist in 2005,<ref name="SoS_asc" /> LabLynx, Inc. went on to diversify its offerings. LabLynx’s browser-based LIMS previously demonstrated at Pittcon in 1997 expanded to become ELab, which in 2001 took on an application service provider (ASP) model of distribution.<ref name="LS_prod2">{{cite web \|url=http://www.limsource.com/products/vatlanta.html \|archiveurl= http://web.archive.org/web/20010409200118/http://www.limsource.com/products/vatlanta.html \|archivedate=9 April 2001 \|title=LIMSource: LIMS Vendor: Atlanta Systems Consultants, Inc. \|accessdate=22 October 2011}}</ref> In 2004 LabLynx released a browser-based tool called openLIMS, which gave consultants and end-users the ability "to build custom LIMS solutions that are geared to the exact operational needs of many different laboratories."<ref>{{cite web \|url=http://www.laboratorytalk.com/news/lbl/lbl100.html \|archiveurl=https://web.archive.org/web/20120419143618/http://www.laboratorytalk.com/news/lbl/lbl100.html \|title=Build your own LIMS: News from LabLynx \|work=LaboratoryTalk.com \|publisher=Pro-Talk Ltd \|date=6 January 2004 \|accessdate=29 December 2015 \|archivedate=19 April 2012}}</ref>		By July 2000, the LabLynx division of ASC separated to become its own incorporated entity.<ref name="SoS_llx" /> And while ASC eventually ceased to exist in 2005,<ref name="SoS_asc" /> LabLynx, Inc. went on to diversify its offerings. LabLynx’s browser-based LIMS previously demonstrated at Pittcon in 1997 expanded to become ELab, which in 2001 took on an application service provider (ASP) model of distribution.<ref name="LS_prod2">{{cite web \|url=http://www.limsource.com/products/vatlanta.html \|archiveurl= http://web.archive.org/web/20010409200118/http://www.limsource.com/products/vatlanta.html \|archivedate=9 April 2001 \|title=LIMSource: LIMS Vendor: Atlanta Systems Consultants, Inc. \|accessdate=22 October 2011}}</ref> In 2004 LabLynx released a browser-based tool called openLIMS, which gave consultants and end-users the ability "to build custom LIMS solutions that are geared to the exact operational needs of many different laboratories."<ref>{{cite web \|url=http://www.laboratorytalk.com/news/lbl/lbl100.html \|archiveurl=https://web.archive.org/web/20120419143618/http://www.laboratorytalk.com/news/lbl/lbl100.html \|title=Build your own LIMS: News from LabLynx \|work=LaboratoryTalk.com \|publisher=Pro-Talk Ltd \|date=6 January 2004 \|accessdate=29 December 2015 \|archivedate=19 April 2012}}</ref>

	On June 19, 2006, LabLynx established the Laboratory Informatics Institute, an open membership group with the purpose of advancing the field of laboratory informatics and shaping the standards associated with it.<ref name="LII">{{cite web \|title=Laboratory Informatics Institute Established \|url=http://www.limsfinder.com/BlogDetail.aspx?id=31049_0_3_0_C \|archiveurl=https://web.archive.org/web/20161027121044/http://www.limsfinder.com/BlogDetail.aspx?id=31049_0_3_0_C \|publisher=Laboratory Informatics Institute, Inc. \|date=17 July 2006 \|archivedate=27 October 2016 \|accessdate=26 January 2018}}</ref> LabLynx made further moves to better its LIMS offerings in August 2008, renewing and expanding its contract with Nagarro, Inc., a U.S.-based technology consulting firm. The collaboration allowed LabLynx to upgrade its existing LIMS software to .NET architecture and expand its initiative to create and market a SaaS-based LIMS.<ref name="Nagarro1">{{cite web \|url=http://www.nagarro.com/NewsEvents/Press%20Releases/LABLynx%20Extends%20Contract%20with.aspx \|archiveurl=https://web.archive.org/web/20120716033503/http://nagarro.com/NewsEvents/Press%20Releases/LABLynx%20Extends%20Contract%20with.aspx \|title=LABLynx Extends Contract with Nagarro to Include Additional Product Development and SaaS Projects \|publisher=Nagarro, Inc \|date=20 August 2008 \|accessdate=29 December 2015 \|archivedate=16 July 2012}}</ref> Less than a year after the announced renewed partnership, LabLynx revealed its redeveloped webLIMS product to the public, featuring ELab in a SaaS model and additional integration of developer tools to allow users to create and modify modules for the LIMS.<ref name="webLIMS1">{{cite web \|title=LabLynx launches the new webLiMS.com, Laboratory SaaS Provider \|url=http://scienceandresearch.argylenews.com/press_release.aspx?LabLynx-launches-the-new-webLiMScom-Laboratory-SaaS-Provider-542 \|archiveurl=https://web.archive.org/web/20160304101223/http://scienceandresearch.argylenews.com/press_release.aspx?LabLynx-launches-the-new-webLiMScom-Laboratory-SaaS-Provider-542 \|publisher=Argyle News \|date=6 March 2009 \|archivedate=04 March 2016 \|accessdate=26 January 2018}}</ref><ref name="webLIMS2">{{cite web \|title=Weblims – LabLynx \|url=https://www.scientific-computing.com/press-releases/weblims \|publisher=Scientific Computing World \|date=6 March 2009 \|accessdate=26 January 2018}}</ref> This move to a cloud-based SaaS model brought renewed interest in the company’s LIMS, with clients like the Georgia Department of Agriculture<ref name="ChemEng1">{{cite web \|url=~~http~~://cen.acs.org/articles/88/i21/LIMS-Cloud.html \|title=LIMS In The Cloud \|author=Mullin, Rick \|work=Chemical & Engineering News \|publisher=American Chemical Society \|date=24 May 2010 \|accessdate=~~29 December 2015~~}}</ref> and Cypress Bioscience<ref>{{cite web \|url=~~http~~://www.pharmaceuticalonline.com/doc/saas-model-turns-lims-paradigm-on-its-0001 \|title=SaaS Model Turns LIMS Paradigm On Its Head \|author=Dubin, Cindy \|publisher=VertMarkets, Inc \|work=Pharmaceutical Online \|date=29 July 2010 \|accessdate=~~29 December 2015~~}}</ref><ref>{{cite web \|title=SaaS - Is a web hosted LIMS right for your laboratory? \|url=http://www.lablynx.com/ArticlesBlogs/tabid/326/articleType/ArticleView/articleId/13/SaaS--Is-a-web-hosted-LIMS-right-for-your-laboratory.aspx \|archiveurl=https://web.archive.org/web/20120509064611/http://www.lablynx.com/ArticlesBlogs/tabid/326/articleType/ArticleView/articleId/13/SaaS--Is-a-web-hosted-LIMS-right-for-your-laboratory.aspx \|publisher=LabLynx, Inc \|date=15 August 2009 \|accessdate=29 December 2015 \|archivedate=09 May 2012}}</ref> taking on the new LIMS.		On June 19, 2006, LabLynx established the Laboratory Informatics Institute, an open membership group with the purpose of advancing the field of laboratory informatics and shaping the standards associated with it.<ref name="LII">{{cite web \|title=Laboratory Informatics Institute Established \|url=http://www.limsfinder.com/BlogDetail.aspx?id=31049_0_3_0_C \|archiveurl=https://web.archive.org/web/20161027121044/http://www.limsfinder.com/BlogDetail.aspx?id=31049_0_3_0_C \|publisher=Laboratory Informatics Institute, Inc. \|date=17 July 2006 \|archivedate=27 October 2016 \|accessdate=26 January 2018}}</ref> LabLynx made further moves to better its LIMS offerings in August 2008, renewing and expanding its contract with Nagarro, Inc., a U.S.-based technology consulting firm. The collaboration allowed LabLynx to upgrade its existing LIMS software to .NET architecture and expand its initiative to create and market a SaaS-based LIMS.<ref name="Nagarro1">{{cite web \|url=http://www.nagarro.com/NewsEvents/Press%20Releases/LABLynx%20Extends%20Contract%20with.aspx \|archiveurl=https://web.archive.org/web/20120716033503/http://nagarro.com/NewsEvents/Press%20Releases/LABLynx%20Extends%20Contract%20with.aspx \|title=LABLynx Extends Contract with Nagarro to Include Additional Product Development and SaaS Projects \|publisher=Nagarro, Inc \|date=20 August 2008 \|accessdate=29 December 2015 \|archivedate=16 July 2012}}</ref> Less than a year after the announced renewed partnership, LabLynx revealed its redeveloped webLIMS product to the public, featuring ELab in a SaaS model and additional integration of developer tools to allow users to create and modify modules for the LIMS.<ref name="webLIMS1">{{cite web \|title=LabLynx launches the new webLiMS.com, Laboratory SaaS Provider \|url=http://scienceandresearch.argylenews.com/press_release.aspx?LabLynx-launches-the-new-webLiMScom-Laboratory-SaaS-Provider-542 \|archiveurl=https://web.archive.org/web/20160304101223/http://scienceandresearch.argylenews.com/press_release.aspx?LabLynx-launches-the-new-webLiMScom-Laboratory-SaaS-Provider-542 \|publisher=Argyle News \|date=6 March 2009 \|archivedate=04 March 2016 \|accessdate=26 January 2018}}</ref><ref name="webLIMS2">{{cite web \|title=Weblims – LabLynx \|url=https://www.scientific-computing.com/press-releases/weblims \|publisher=Scientific Computing World \|date=6 March 2009 \|accessdate=26 January 2018}}</ref> This move to a cloud-based SaaS model brought renewed interest in the company’s LIMS, with clients like the Georgia Department of Agriculture<ref name="ChemEng1">{{cite web \|url=https://cen.acs.org/articles/88/i21/LIMS-Cloud.html \|title=LIMS In The Cloud \|author=Mullin, Rick \|work=Chemical & Engineering News \|publisher=American Chemical Society \|date=24 May 2010 \|accessdate=24 September 2021}}</ref> and Cypress Bioscience<ref>{{cite web \|url=https://www.pharmaceuticalonline.com/doc/saas-model-turns-lims-paradigm-on-its-0001 \|title=SaaS Model Turns LIMS Paradigm On Its Head \|author=Dubin, Cindy \|publisher=VertMarkets, Inc \|work=Pharmaceutical Online \|date=29 July 2010 \|accessdate=24 September 2021}}</ref><ref>{{cite web \|title=SaaS - Is a web hosted LIMS right for your laboratory? \|url=http://www.lablynx.com/ArticlesBlogs/tabid/326/articleType/ArticleView/articleId/13/SaaS--Is-a-web-hosted-LIMS-right-for-your-laboratory.aspx \|archiveurl=https://web.archive.org/web/20120509064611/http://www.lablynx.com/ArticlesBlogs/tabid/326/articleType/ArticleView/articleId/13/SaaS--Is-a-web-hosted-LIMS-right-for-your-laboratory.aspx \|publisher=LabLynx, Inc \|date=15 August 2009 \|accessdate=29 December 2015 \|archivedate=09 May 2012}}</ref> taking on the new LIMS.

	In 2011, LabLynx was involved in an initiative to standardize and structure the transmission of laboratory data that first originates in a LIMS or LIS and then moves to a person's or population of people's [[electronic health record]]s.<ref>{{cite book \|title=Laboratory Results Interface (LRI) Pilots Guide \|edition= v0.9.4.093011 \|author=Clarke, Ann \| year=2011 \|pages=1–2 \|publisher=LabLynx/mdDigest \|url=http://wiki.siframework.org/file/view/LRI_Pilots_Guide_Draft_v0_9_4_093011.docx \|archiveurl=https://web.archive.org/web/20140812142427/http://wiki.siframework.org/file/view/LRI_Pilots_Guide_Draft_v0_9_4_093011.docx \|archivedate=12 August 2014}}</ref> This laboratory results interface (LRI) pilot began in August 2011 and included collaborations with the supported open source project mdDigest and the U.S. Office of the National Coordinator for Health Information Technology (ONC).<ref>{{cite web \|title=PROJECT BRIEF: LabLynx/mdDigest Pilot \|url=http://wiki.siframework.org/LabLynx+Pilot+Brief \|archiveurl=https://web.archive.org/web/20140812142106/http://wiki.siframework.org/LabLynx+Pilot+Brief \|publisher= LabLynx/mdDigest \|archivedate=12 August 2016 \|accessdate=16 January 2018}}</ref>		In 2011, LabLynx was involved in an initiative to standardize and structure the transmission of laboratory data that first originates in a LIMS or LIS and then moves to a person's or population of people's [[electronic health record]]s.<ref>{{cite book \|title=Laboratory Results Interface (LRI) Pilots Guide \|edition= v0.9.4.093011 \|author=Clarke, Ann \| year=2011 \|pages=1–2 \|publisher=LabLynx/mdDigest \|url=http://wiki.siframework.org/file/view/LRI_Pilots_Guide_Draft_v0_9_4_093011.docx \|archiveurl=https://web.archive.org/web/20140812142427/http://wiki.siframework.org/file/view/LRI_Pilots_Guide_Draft_v0_9_4_093011.docx \|archivedate=12 August 2014}}</ref> This laboratory results interface (LRI) pilot began in August 2011 and included collaborations with the supported open source project mdDigest and the U.S. Office of the National Coordinator for Health Information Technology (ONC).<ref>{{cite web \|title=PROJECT BRIEF: LabLynx/mdDigest Pilot \|url=http://wiki.siframework.org/LabLynx+Pilot+Brief \|archiveurl=https://web.archive.org/web/20140812142106/http://wiki.siframework.org/LabLynx+Pilot+Brief \|publisher= LabLynx/mdDigest \|archivedate=12 August 2016 \|accessdate=16 January 2018}}</ref>

	In February 2015, LabLynx announced the introduction of HealthCloudPOL, a cloud-based [[laboratory information system]] (LIS) for the physician office laboratory (POL), making the basic starter package free to users.<ref name="HCPOL_LinkedIn">{{cite web \|url=https://www.linkedin.com/company/lablynx-inc./comments?topic=5979788253375520768&type=U&scope=209217&stype=C&a=NHFX \|title=Security, Reliability, and Regulatory Compliance: healthcloudpol.com \|author=LabLynx, Inc \|publisher=LinkedIn Corporation \|date=February 2015 \|accessdate=29 December 2015}}</ref><ref name="HCPOLArch">{{cite web \|url=http://www.healthcloudpol.com/ \|archiveurl=https://web.archive.org/web/20150314182554/www.healthcloudpol.com \|title=HealthCloudPOL — the FREE Cloud-based Physician Office LIS \|publisher=LabLynx, Inc \|archivedate=14 March 2015 \|accessdate=26 January 2018}}</ref> That product line soon after changed names, becoming sciCloud.net~~, though as of January 2018 that product line had not fully launched~~.		In February 2015, LabLynx announced the introduction of HealthCloudPOL, a cloud-based [[laboratory information system]] (LIS) for the physician office laboratory (POL), making the basic starter package free to users.<ref name="HCPOL_LinkedIn">{{cite web \|url=https://www.linkedin.com/company/lablynx-inc./comments?topic=5979788253375520768&type=U&scope=209217&stype=C&a=NHFX \|title=Security, Reliability, and Regulatory Compliance: healthcloudpol.com \|author=LabLynx, Inc \|publisher=LinkedIn Corporation \|date=February 2015 \|accessdate=29 December 2015}}</ref><ref name="HCPOLArch">{{cite web \|url=http://www.healthcloudpol.com/ \|archiveurl=https://web.archive.org/web/20150314182554/www.healthcloudpol.com \|title=HealthCloudPOL — the FREE Cloud-based Physician Office LIS \|publisher=LabLynx, Inc \|archivedate=14 March 2015 \|accessdate=26 January 2018}}</ref> That product line soon after changed names, becoming sciCloud.net.

	In the summer of 2019, LabLynx released its CannaQA LIMS software for the cannabis testing industry.<ref name="LLPWelcome19">{{cite web \|url=https://www.lablynxpress.com/index.php?title=Welcome_to_CannaQA \|title=Welcome to CannaQA \|work=LabLynx Press \|publisher=LabLynx, Inc \|date=11 July 2019 \|accessdate=02 March 2020}}</ref>		In the summer of 2019, LabLynx released its CannaQA LIMS software for the cannabis testing industry.<ref name="LLPWelcome19">{{cite web \|url=https://www.lablynxpress.com/index.php?title=Welcome_to_CannaQA \|title=Welcome to CannaQA \|work=LabLynx Press \|publisher=LabLynx, Inc \|date=11 July 2019 \|accessdate=02 March 2020}}</ref>
Line 74:		Line 74:

	===Community history===		===Community history===
	Since transitioning from Atlanta Systems Consultants, Inc. to LabLynx, Inc. in 2000, LabLynx has become increasingly active in the laboratory informatics community. Projects that LabLynx has started or been involved in within the community include:		Since transitioning from Atlanta Systems Consultants, Inc. to LabLynx, Inc. in 2000, LabLynx has become increasingly active in the laboratory informatics community. Projects that LabLynx has started or been involved in within the community over the years include:

	* the Laboratory Informatics Institute, an open trade association with the mission of educating, standardizing, and promoting the laboratory informatics industry<ref name="LII" />		* the Laboratory Informatics Institute, an open trade association with the mission of educating, standardizing, and promoting the laboratory informatics industry<ref name="LII" />
Line 81:		Line 81:
	* LIMSforum, a LinkedIn discussion group created to facilitate the exchange of ideas and technical information across the fields of laboratory, science, and [[health informatics]]<ref>{{cite web \|url=http://www.laboratorytalk.com/news/lbl/lbl103.html \|archiveurl=https://web.archive.org/web/20120419143627/http://www.laboratorytalk.com/news/lbl/lbl103.html \|title=Lablynx - latest company news \|work=LaboratoryTalk.com \|publisher=Pro-Talk Ltd \|date=25 August 2009 \|accessdate=29 December 2015 \|archivedate=19 April 2012}}</ref><ref>{{cite web \|title=LiMS forum - Laboratory Informatics Institute user's group for LIMS, Scientific & Health Informatics \|url=http://www.linkedin.com/groups?about=&gid=2069898 \|publisher=LinkedIn.com \|accessdate=22 October 2011}}</ref>; this later became a stand-alone community web portal.<ref name="LIMSForumSite">{{cite web \|url=https://www.limsforum.com/ \|title=LiMSForum \|publisher=LabLynx, Inc \|accessdate=26 January 2018}}</ref>		* LIMSforum, a LinkedIn discussion group created to facilitate the exchange of ideas and technical information across the fields of laboratory, science, and [[health informatics]]<ref>{{cite web \|url=http://www.laboratorytalk.com/news/lbl/lbl103.html \|archiveurl=https://web.archive.org/web/20120419143627/http://www.laboratorytalk.com/news/lbl/lbl103.html \|title=Lablynx - latest company news \|work=LaboratoryTalk.com \|publisher=Pro-Talk Ltd \|date=25 August 2009 \|accessdate=29 December 2015 \|archivedate=19 April 2012}}</ref><ref>{{cite web \|title=LiMS forum - Laboratory Informatics Institute user's group for LIMS, Scientific & Health Informatics \|url=http://www.linkedin.com/groups?about=&gid=2069898 \|publisher=LinkedIn.com \|accessdate=22 October 2011}}</ref>; this later became a stand-alone community web portal.<ref name="LIMSForumSite">{{cite web \|url=https://www.limsforum.com/ \|title=LiMSForum \|publisher=LabLynx, Inc \|accessdate=26 January 2018}}</ref>
	* LIMSuniversity, an open-access learning resource released by the Laboratory Informatics Institute, targeted towards laboratories and the LIMS community<ref>{{cite web \|title=LiMSuniversity.com, the on-line, Open Access, Virtual Learning Center for Laboratory Informatics users and professionals \|url=http://www.limsfinder.com/BlogDetail.aspx?id=35134_0_25_0_C \|archiveurl=https://web.archive.org/web/20170306214123/http://www.limsfinder.com/BlogDetail.aspx?id=35134_0_25_0_C \|publisher=Laboratory Informatics Institute, Inc. \|date=4 April 2011 \|archivedate=06 March 2017 \|accessdate=26 January 2018}}</ref>		* LIMSuniversity, an open-access learning resource released by the Laboratory Informatics Institute, targeted towards laboratories and the LIMS community<ref>{{cite web \|title=LiMSuniversity.com, the on-line, Open Access, Virtual Learning Center for Laboratory Informatics users and professionals \|url=http://www.limsfinder.com/BlogDetail.aspx?id=35134_0_25_0_C \|archiveurl=https://web.archive.org/web/20170306214123/http://www.limsfinder.com/BlogDetail.aspx?id=35134_0_25_0_C \|publisher=Laboratory Informatics Institute, Inc. \|date=4 April 2011 \|archivedate=06 March 2017 \|accessdate=26 January 2018}}</ref>
	* LIMSwiki, a Creative Commons-licensed wiki with the goal of bringing related informatics communities together to maintain a repository of information about the industry<ref>{{cite web\|title=LIMSwiki mission \|url=https://www.limswiki.org/index.php/LIMSwiki_mission \|date=4 June 2015 \|accessdate=26 January 2018}}</ref>		* LIMSwiki, a Creative Commons-licensed wiki with the goal of bringing related informatics communities together to maintain a repository of information about the industry<ref>{{cite web \|title=LIMSwiki mission \|url=https://www.limswiki.org/index.php/LIMSwiki_mission \|date=4 June 2015 \|accessdate=26 January 2018}}</ref>
			* CannaQAwiki, a Creative Commons-licensed wiki with the goal of providing content as it relates to analytically testing the ''Cannabis'' plant and its constituents in the laboratory, as well as the regulatory aspects that surround it<ref>{{cite web \|title=Welcome to CannaQAwiki \|url=https://www.cannaqa.wiki/index.php?title=Main_Page \|date=03 September 2021 \|accessdate=24 September 2021}}</ref>

	==Technology and products==		==Technology and products==

Shawndouglas: /* Sandbox begins below */

2021-09-24T16:46:33Z

Sandbox begins below

Show changes

Shawndouglas: Replaced content with "
TOC
{{ombox | type = notice | style = width: 960px; | text = This is my primary sandbox page, where I play with features and..."

2021-09-19T16:34:35Z

Replaced content with "<div class="nonumtoc">__TOC__</div> {{ombox | type = notice | style = width: 960px; | text = This is my primary sandbox page, where I play with features and..."

← Older revision		Revision as of 16:34, 19 September 2021
Line 7:		Line 7:

	==Sandbox begins below==		==Sandbox begins below==

	~~====3.1.7 Multiplex testing====~~
	As the pandemic has progressed and test manufacturers have become more experienced with SARS-CoV-2 test development, multiplex testing has become an option. The multiplex assay—an immunoassay test able to measure multiple analytes in a single test—is certainly not new in itself. In 1989, R. Ekins developed the ambient analyte theory, which stated that miniaturizing an immunoassay can lead to an improved limit of detection (LOD). That work influenced the future development of microarray multiplex technology principles.<ref name="TigheELISA15">{{Cite journal \|last=Tighe \|first=Patrick J. \|last2=Ryder \|first2=Richard R. \|last3=Todd \|first3=Ian \|last4=Fairclough \|first4=Lucy C. \|date=2015-04 \|title=ELISA in the multiplex era: Potentials and pitfalls \|url=https://onlinelibrary.wiley.com/doi/10.1002/prca.201400130 \|journal=PROTEOMICS – Clinical Applications \|language=en \|volume=9 \|issue=3-4 \|pages=406–422 \|doi=10.1002/prca.201400130 \|issn=1862-8346 \|pmc=PMC6680274 \|pmid=25644123}}</ref> By 2013, development of multiplex protein immunoassays was becoming increasingly prominent.<ref name="TigheELISA15" />

	As of September 2021, eighteen "multi-analyte" ''in vitro'' molecular diagnostic tests are shown as receiving EUAs by the FDA, four of them even authorized for CLIA waived testing.<ref name="FDAInVitroEUAs21">{{cite web \|url=https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2 \|title=In Vitro Diagnostics EUAs - Molecular Diagnostic Tests for SARS-CoV-2 \|publisher=U.S. Food and Drug Administration \|date=07 September 2021 \|accessdate=07 September 2021}}</ref> Common additional targets for analysis among the various kits include influenza A, influenza B, and respiratory syncytial virus (RSV).<ref name="FDAInVitroEUAs21" /> However, several multiplex test kits cover an even broader array of respiratory-affecting organism types and subtypes such as adenovirus and a few other coronavirus types, to name a few. Kits include the ePlex Respiratory Pathogen Panel 2<ref name="HintonePlex20">{{cite web \|url=https://www.fda.gov/media/142902/download \|format=PDF \|title=ePlex Respiratory Pathogen Panel 2 (ePlex RP2 Panel) \|author=Hinton, D.M. \|publisher=U.S. Food and Drug Administration \|date=07 October 2020 \|accessdate=19 September 2021}}</ref>, the NxTAG Respiratory Pathogen Panel + SARS-CoV-2<ref name="HintonNxTAG21">{{cite web \|url=https://www.fda.gov/media/146492/download \|format=PDF \|title=NxTAG Respiratory Pathogen Panel + SARS-CoV-2 \|author=Hinton, D.M. \|publisher=U.S. Food and Drug Administration \|date=03 March 2021 \|accessdate=19 September 2021}}</ref>, the QIAstat-Dx Respiratory SARS-CoV-2 Panel<ref name="HintonQIAstat21">{{cite web \|url=https://www.fda.gov/media/136569/download \|format=PDF \|title=QIAstat-Dx Respiratory SARS-CoV-2 Panel \|author=Hinton, D.M. \|publisher=U.S. Food and Drug Administration \|date=29 July 2021 \|accessdate=19 September 2021}}</ref>, and the BioFire Respiratory Panel 2.1-EZ.<ref name="HintonBioFireRes21">{{cite web \|url=https://www.fda.gov/media/142693/download \|format=PDF \|title=BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ) \|author=Hinton, D.M. \|publisher=U.S. Food and Drug Administration \|date=30 August 2021 \|accessdate=19 September 2021}}</ref> (Of the four, the BioFire panel is approved for CLIA waived testing.<ref name="FDAInVitroEUAs21" />)

	Multiplexing provides a variety of benefits for laboratories and patients. In their 2015 paper on ELISA and multiplex technologies, Tighe ''et al'' find that multiplexed immunoassays have the potential to decrease diagnosis times and reduce assay costs. "At the same time, such multiplexing offers more comprehensive analysis whether for research purposes, differential diagnoses, or monitoring of therapeutic interventions."<ref name="TigheELISA15" /> They also note the potential for improved health surveillance of patients, catching early-onset diseases by looking for informative biomarkers.<ref name="TigheELISA15" /> From the perspective of diagnosing infections of SARS-CoV-2 or influenza, the CDC adds that multiplexing helps preserve testing supplies that may be in short supply, conduct more tests in a given time period, and paint a clearer picture of both viruses and their prevalence in a given population.<ref name="CDCInflu21">{{cite web \|url=https://www.cdc.gov/coronavirus/2019-ncov/lab/multiplex.html \|title=CDC’s Influenza SARS-CoV-2 Multiplex Assay and Required Supplies \|author=Centers for Disease Control and Prevention \|publisher=Centers for Disease Control and Prevention \|date=13 July 2021 \|accessdate=19 September 2021}}</ref>

Shawndouglas at 16:20, 19 September 2021

2021-09-19T16:20:02Z

← Older revision		Revision as of 16:20, 19 September 2021
Line 13:		Line 13:
	As of September 2021, eighteen "multi-analyte" ''in vitro'' molecular diagnostic tests are shown as receiving EUAs by the FDA, four of them even authorized for CLIA waived testing.<ref name="FDAInVitroEUAs21">{{cite web \|url=https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2 \|title=In Vitro Diagnostics EUAs - Molecular Diagnostic Tests for SARS-CoV-2 \|publisher=U.S. Food and Drug Administration \|date=07 September 2021 \|accessdate=07 September 2021}}</ref> Common additional targets for analysis among the various kits include influenza A, influenza B, and respiratory syncytial virus (RSV).<ref name="FDAInVitroEUAs21" /> However, several multiplex test kits cover an even broader array of respiratory-affecting organism types and subtypes such as adenovirus and a few other coronavirus types, to name a few. Kits include the ePlex Respiratory Pathogen Panel 2<ref name="HintonePlex20">{{cite web \|url=https://www.fda.gov/media/142902/download \|format=PDF \|title=ePlex Respiratory Pathogen Panel 2 (ePlex RP2 Panel) \|author=Hinton, D.M. \|publisher=U.S. Food and Drug Administration \|date=07 October 2020 \|accessdate=19 September 2021}}</ref>, the NxTAG Respiratory Pathogen Panel + SARS-CoV-2<ref name="HintonNxTAG21">{{cite web \|url=https://www.fda.gov/media/146492/download \|format=PDF \|title=NxTAG Respiratory Pathogen Panel + SARS-CoV-2 \|author=Hinton, D.M. \|publisher=U.S. Food and Drug Administration \|date=03 March 2021 \|accessdate=19 September 2021}}</ref>, the QIAstat-Dx Respiratory SARS-CoV-2 Panel<ref name="HintonQIAstat21">{{cite web \|url=https://www.fda.gov/media/136569/download \|format=PDF \|title=QIAstat-Dx Respiratory SARS-CoV-2 Panel \|author=Hinton, D.M. \|publisher=U.S. Food and Drug Administration \|date=29 July 2021 \|accessdate=19 September 2021}}</ref>, and the BioFire Respiratory Panel 2.1-EZ.<ref name="HintonBioFireRes21">{{cite web \|url=https://www.fda.gov/media/142693/download \|format=PDF \|title=BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ) \|author=Hinton, D.M. \|publisher=U.S. Food and Drug Administration \|date=30 August 2021 \|accessdate=19 September 2021}}</ref> (Of the four, the BioFire panel is approved for CLIA waived testing.<ref name="FDAInVitroEUAs21" />)		As of September 2021, eighteen "multi-analyte" ''in vitro'' molecular diagnostic tests are shown as receiving EUAs by the FDA, four of them even authorized for CLIA waived testing.<ref name="FDAInVitroEUAs21">{{cite web \|url=https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2 \|title=In Vitro Diagnostics EUAs - Molecular Diagnostic Tests for SARS-CoV-2 \|publisher=U.S. Food and Drug Administration \|date=07 September 2021 \|accessdate=07 September 2021}}</ref> Common additional targets for analysis among the various kits include influenza A, influenza B, and respiratory syncytial virus (RSV).<ref name="FDAInVitroEUAs21" /> However, several multiplex test kits cover an even broader array of respiratory-affecting organism types and subtypes such as adenovirus and a few other coronavirus types, to name a few. Kits include the ePlex Respiratory Pathogen Panel 2<ref name="HintonePlex20">{{cite web \|url=https://www.fda.gov/media/142902/download \|format=PDF \|title=ePlex Respiratory Pathogen Panel 2 (ePlex RP2 Panel) \|author=Hinton, D.M. \|publisher=U.S. Food and Drug Administration \|date=07 October 2020 \|accessdate=19 September 2021}}</ref>, the NxTAG Respiratory Pathogen Panel + SARS-CoV-2<ref name="HintonNxTAG21">{{cite web \|url=https://www.fda.gov/media/146492/download \|format=PDF \|title=NxTAG Respiratory Pathogen Panel + SARS-CoV-2 \|author=Hinton, D.M. \|publisher=U.S. Food and Drug Administration \|date=03 March 2021 \|accessdate=19 September 2021}}</ref>, the QIAstat-Dx Respiratory SARS-CoV-2 Panel<ref name="HintonQIAstat21">{{cite web \|url=https://www.fda.gov/media/136569/download \|format=PDF \|title=QIAstat-Dx Respiratory SARS-CoV-2 Panel \|author=Hinton, D.M. \|publisher=U.S. Food and Drug Administration \|date=29 July 2021 \|accessdate=19 September 2021}}</ref>, and the BioFire Respiratory Panel 2.1-EZ.<ref name="HintonBioFireRes21">{{cite web \|url=https://www.fda.gov/media/142693/download \|format=PDF \|title=BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ) \|author=Hinton, D.M. \|publisher=U.S. Food and Drug Administration \|date=30 August 2021 \|accessdate=19 September 2021}}</ref> (Of the four, the BioFire panel is approved for CLIA waived testing.<ref name="FDAInVitroEUAs21" />)

	Multiplexing provides a variety of benefits for laboratories and patients.		Multiplexing provides a variety of benefits for laboratories and patients. In their 2015 paper on ELISA and multiplex technologies, Tighe ''et al'' find that multiplexed immunoassays have the potential to decrease diagnosis times and reduce assay costs. "At the same time, such multiplexing offers more comprehensive analysis whether for research purposes, differential diagnoses, or monitoring of therapeutic interventions."<ref name="TigheELISA15" /> They also note the potential for improved health surveillance of patients, catching early-onset diseases by looking for informative biomarkers.<ref name="TigheELISA15" /> From the perspective of diagnosing infections of SARS-CoV-2 or influenza, the CDC adds that multiplexing helps preserve testing supplies that may be in short supply, conduct more tests in a given time period, and paint a clearer picture of both viruses and their prevalence in a given population.<ref name="CDCInflu21">{{cite web \|url=https://www.cdc.gov/coronavirus/2019-ncov/lab/multiplex.html \|title=CDC’s Influenza SARS-CoV-2 Multiplex Assay and Required Supplies \|author=Centers for Disease Control and Prevention \|publisher=Centers for Disease Control and Prevention \|date=13 July 2021 \|accessdate=19 September 2021}}</ref>

Shawndouglas at 15:51, 19 September 2021

2021-09-19T15:51:02Z

← Older revision		Revision as of 15:51, 19 September 2021
Line 9:		Line 9:

	====3.1.7 Multiplex testing====		====3.1.7 Multiplex testing====
	As the pandemic has progressed and test manufacturers have become more experienced with SARS-CoV-2 test development, multiplex testing has become an option. The multiplex assay—an immunoassay test able to measure multiple analytes in a single test—is certainly not new in itself. In 1989, R. Ekins developed the ambient analyte theory, which stated that miniaturizing an immunoassay can lead to an improved limit of detection (LOD). That work influenced the future development of microarray multiplex technology principles.<ref name="TigheELISA15">{{Cite journal \|last=Tighe \|first=Patrick J. \|last2=Ryder \|first2=Richard R. \|last3=Todd \|first3=Ian \|last4=Fairclough \|first4=Lucy C. \|date=2015-04 \|title=ELISA in the multiplex era: Potentials and pitfalls \|url=https://onlinelibrary.wiley.com/doi/10.1002/prca.201400130 \|journal=PROTEOMICS – Clinical Applications \|language=en \|volume=9 \|issue=3-4 \|pages=406–422 \|doi=10.1002/prca.201400130 \|issn=1862-8346 \|pmc=PMC6680274 \|pmid=25644123}}</ref> As of September 2021, eighteen ''in vitro'' molecular diagnostic tests are shown as receiving EUAs by the FDA, four of them even authorized for CLIA waived testing.		As the pandemic has progressed and test manufacturers have become more experienced with SARS-CoV-2 test development, multiplex testing has become an option. The multiplex assay—an immunoassay test able to measure multiple analytes in a single test—is certainly not new in itself. In 1989, R. Ekins developed the ambient analyte theory, which stated that miniaturizing an immunoassay can lead to an improved limit of detection (LOD). That work influenced the future development of microarray multiplex technology principles.<ref name="TigheELISA15">{{Cite journal \|last=Tighe \|first=Patrick J. \|last2=Ryder \|first2=Richard R. \|last3=Todd \|first3=Ian \|last4=Fairclough \|first4=Lucy C. \|date=2015-04 \|title=ELISA in the multiplex era: Potentials and pitfalls \|url=https://onlinelibrary.wiley.com/doi/10.1002/prca.201400130 \|journal=PROTEOMICS – Clinical Applications \|language=en \|volume=9 \|issue=3-4 \|pages=406–422 \|doi=10.1002/prca.201400130 \|issn=1862-8346 \|pmc=PMC6680274 \|pmid=25644123}}</ref> By 2013, development of multiplex protein immunoassays was becoming increasingly prominent.<ref name="TigheELISA15" />

			As of September 2021, eighteen "multi-analyte" ''in vitro'' molecular diagnostic tests are shown as receiving EUAs by the FDA, four of them even authorized for CLIA waived testing.<ref name="FDAInVitroEUAs21">{{cite web \|url=https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2 \|title=In Vitro Diagnostics EUAs - Molecular Diagnostic Tests for SARS-CoV-2 \|publisher=U.S. Food and Drug Administration \|date=07 September 2021 \|accessdate=07 September 2021}}</ref> Common additional targets for analysis among the various kits include influenza A, influenza B, and respiratory syncytial virus (RSV).<ref name="FDAInVitroEUAs21" /> However, several multiplex test kits cover an even broader array of respiratory-affecting organism types and subtypes such as adenovirus and a few other coronavirus types, to name a few. Kits include the ePlex Respiratory Pathogen Panel 2<ref name="HintonePlex20">{{cite web \|url=https://www.fda.gov/media/142902/download \|format=PDF \|title=ePlex Respiratory Pathogen Panel 2 (ePlex RP2 Panel) \|author=Hinton, D.M. \|publisher=U.S. Food and Drug Administration \|date=07 October 2020 \|accessdate=19 September 2021}}</ref>, the NxTAG Respiratory Pathogen Panel + SARS-CoV-2<ref name="HintonNxTAG21">{{cite web \|url=https://www.fda.gov/media/146492/download \|format=PDF \|title=NxTAG Respiratory Pathogen Panel + SARS-CoV-2 \|author=Hinton, D.M. \|publisher=U.S. Food and Drug Administration \|date=03 March 2021 \|accessdate=19 September 2021}}</ref>, the QIAstat-Dx Respiratory SARS-CoV-2 Panel<ref name="HintonQIAstat21">{{cite web \|url=https://www.fda.gov/media/136569/download \|format=PDF \|title=QIAstat-Dx Respiratory SARS-CoV-2 Panel \|author=Hinton, D.M. \|publisher=U.S. Food and Drug Administration \|date=29 July 2021 \|accessdate=19 September 2021}}</ref>, and the BioFire Respiratory Panel 2.1-EZ.<ref name="HintonBioFireRes21">{{cite web \|url=https://www.fda.gov/media/142693/download \|format=PDF \|title=BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ) \|author=Hinton, D.M. \|publisher=U.S. Food and Drug Administration \|date=30 August 2021 \|accessdate=19 September 2021}}</ref> (Of the four, the BioFire panel is approved for CLIA waived testing.<ref name="FDAInVitroEUAs21" />)

			Multiplexing provides a variety of benefits for laboratories and patients.

Shawndouglas at 00:15, 19 September 2021

2021-09-19T00:15:38Z

← Older revision		Revision as of 00:15, 19 September 2021
Line 8:		Line 8:
	==Sandbox begins below==		==Sandbox begins below==

	====3.1.~~6 Variant~~ testing====		====3.1.7 Multiplex testing====
	As the pandemic has progressed~~, you may~~ have ~~heard talk of a "delta" variant of~~ SARS-CoV-2, ~~which is reportedly more contagious and virulent than the initial strain that kicked off the pandemic~~.~~<ref name="CDCDelta21">{{cite web \|url=https://www~~.~~cdc~~.~~gov/coronavirus/2019-ncov/variants/delta-variant.html \|title=Delta Variant: What We Know About~~ the Science \|author=Centers for Disease Control and Prevention \|publisher=Centers for Disease Control and Prevention \|date=26 August 2021 \|accessdate=18 September 2021}}</ref> One or more variants of a virus are expected as time progresses, ~~and some of those variants~~ can ~~cause significantly more problems than the source virus. As such, analytical testing of the virus over time is vital~~ to ~~public health.~~		As the pandemic has progressed and test manufacturers have become more experienced with SARS-CoV-2 test development, multiplex testing has become an option. The multiplex assay—an immunoassay test able to measure multiple analytes in a single test—is certainly not new in itself. In 1989, R. Ekins developed the ambient analyte theory, which stated that miniaturizing an immunoassay can lead to an improved limit of detection (LOD). That work influenced the future development of microarray multiplex technology principles.<ref name="TigheELISA15">{{Cite journal \|last=Tighe \|first=Patrick J. \|last2=Ryder \|first2=Richard R. \|last3=Todd \|first3=Ian \|last4=Fairclough \|first4=Lucy C. \|date=2015-04 \|title=ELISA in the multiplex era: Potentials and pitfalls \|url=https://onlinelibrary.wiley.com/doi/10.1002/prca.201400130 \|journal=PROTEOMICS – Clinical Applications \|language=en \|volume=9 \|issue=3-4 \|pages=406–422 \|doi=10.1002/prca.201400130 \|issn=1862-8346 \|pmc=PMC6680274 \|pmid=25644123}}</ref> As of September 2021, eighteen ''in vitro'' molecular diagnostic tests are shown as receiving EUAs by the FDA, four of them even authorized for CLIA waived testing.

	~~The purpose~~ of ~~variant testing can be described in two ways, one for public health reasons and another for clinical care reasons~~. On the ~~public health side, analysis of SARS-CoV-2 variants provides an unbiased, population-level view "~~of ~~the specific viral strains in circulation and monitors changes in the viral genome over time~~."<ref name="~~BuchanSARS21~~">{{~~cite web~~ \|~~url~~=~~https://www.amp.org/AMP/assets/File/clinical-practice/COVID/AMP_RC_VariantTestingforSARSCOV2_4_28_21.pdf~~ \|~~format~~=~~PDF~~ \|~~title~~=~~SARS-CoV-2 Variant Testing~~ \|~~work~~=~~Rapid Communication~~ \|~~author~~=~~Buchan, B.W.; Wolk, D.M.; Yao, J.D.~~ \|~~publisher~~=~~Association for Molecular Pathology~~ \|~~date~~=~~28 April 2021~~ \|~~accessdate~~=18 September 2021}}</ref> With enough public health laboratories conducting this type of analysis—typically whole-genome sequencing (WGS) using [[next-generation sequencing]] (NGS) techniques—a clearer picture of how an outbreak spreads is gained, as well as what variants are taking hold and further threatening human populations (even those that are vaccinated). ~~This information is typically shared through the public health system for surveillance and reporting purposes, though the affected patients themselves may never see the data.<ref name~~=~~"BuchanSARS21" />~~

	~~On the clinical care side, analysis of SARS~~-CoV-2 variants provides further insights into improving COVID-19 patient outcomes. Buchan ''et al.'' identify three potential insights that clinicians may gain, noting that variant testing allows the clinician<ref name=~~"BuchanSARS21" />:~~

	* to distinguish between an existing, persistent infection caused by one viral strain vs. re-infection by a different viral strain;
	* to determine whether a patient not responding to a treatment is affected by a specific viral spike protein (S) gene mutation that is "potentially resistant or less susceptible to
	~~neutralizing antibodies or monoclonal antibodies"; and~~
	* to detect in the ~~serum or plasma of a patient post-vaccination "viral S gene substitutions in specific variants that are potentially resistant or less susceptible" to the antibodies the vaccine generates.~~

	If, for example, a patient is diagnosed with a variant that is tied to heightened disease severity, the clinician can opt for additional treatments early on to counteract the variant's effects on the patient. This testing is done in a hospital or reference lab by WGS or by targeting a portion of the genome (e.g., a spike protein) or a specific mutation (using RT-PCR). However, according to Buchan ''et al.'', the contributions a mutation makes to a "variant's attributes is not entirely understood, and there is no definitive evidence that directly links a given mutation to poor outcomes, significantly reduced efficacy of SARS-CoV-2 therapies, or vaccine coverage."<ref name="BuchanSARS21" />

	~~That said,~~ and leaving the public health element to the side, if you are a laboratory conducting clinical analyses of SARS-CoV-2 specimens, the likelihood of including viral sequencing and sequence analysis for variant testing may be low for your facility. Such testing is a multi-step process requiring a non-trivial set of resources, often available to large commercial diagnostic laboratories.<ref name="BuchanSARS21" /><ref name="WilliamsEnhanc21">{{cite web \|url=https://~~health~~.mo.~~gov~~/~~emergencies~~/~~ert~~/~~alertsadvisories/pdf/update21921~~.~~pdf~~ \|~~format~~=~~PDF \|title=Enhancing Public Health Surveillance for Variant SARSCoV-2 Viruses in Missouri~~ \|~~author~~=~~Williams, R.W.~~ \|~~publisher~~=~~Missouri Department of Health & Senior Services~~ \|~~date~~=~~19 February 2021~~ \|~~accessdate=18 September 2021}}</ref> The CDC represents one possible workflow for genomic sequencing as such<ref name~~=~~"CDCRole21">{{cite web~~ \|~~url~~=~~https://www.cdc~~.~~gov/coronavirus~~/~~2019-ncov/variants/cdc-role-surveillance~~.~~html~~ \|~~title~~=~~CDC’s Role in Tracking Variants~~ \|~~author~~=~~Centers for Disease Control and Prevention~~ \|~~publisher~~=~~Centers for Disease Control and Prevention \|date=08 September 2021 \|accessdate=18 September 2021~~}}</ref>:

	~~# A specimen containing the SARS-CoV-2 virus is received by the lab and promptly entered into the [[laboratory information system]] (LIS).~~
	~~# The RNA~~ of ~~the SARS-CoV-2 virus is extracted from the sample and then converted to complimentary DNA. It is then enriched and loaded into the appropriate NGS instrument.~~
	~~# The instrument runs the sequencing and raw data is collected~~, ~~with~~ the ~~lab maintaining quality control steps. The raw data is turned into actionable sequence data.~~
	~~# The sequence data is verified for suitability~~, ~~with a resequencing occurring if found to be inadequate. Otherwise, the data is then analyzed and interpreted.~~

	If your diagnostic lab has or is planning on adding sequencing tools to supplement clinical diagnostics, it may make sense to consider adding variant testing to your available options. But in reality, this sort of testing ~~may largely be left to large institutions, such as the University of Rochester Vaccine Treatment Evaluation Unit or the Yale School of Public Health~~.<ref name="DupuyCOVID21">{{cite web \|url=https://apnews.com/article/fact-checking-549965482111 \|title=COVID-19 variants tested through genome sequencing \|author=Dupuy, B. \|work=Reuters Fact-Checking \|date=28 July 2021 \|accessdate=18 September 2021}}</ref>

Shawndouglas at 23:05, 18 September 2021

2021-09-18T23:05:29Z

← Older revision		Revision as of 23:05, 18 September 2021
Line 21:		Line 21:

	If, for example, a patient is diagnosed with a variant that is tied to heightened disease severity, the clinician can opt for additional treatments early on to counteract the variant's effects on the patient. This testing is done in a hospital or reference lab by WGS or by targeting a portion of the genome (e.g., a spike protein) or a specific mutation (using RT-PCR). However, according to Buchan ''et al.'', the contributions a mutation makes to a "variant's attributes is not entirely understood, and there is no definitive evidence that directly links a given mutation to poor outcomes, significantly reduced efficacy of SARS-CoV-2 therapies, or vaccine coverage."<ref name="BuchanSARS21" />		If, for example, a patient is diagnosed with a variant that is tied to heightened disease severity, the clinician can opt for additional treatments early on to counteract the variant's effects on the patient. This testing is done in a hospital or reference lab by WGS or by targeting a portion of the genome (e.g., a spike protein) or a specific mutation (using RT-PCR). However, according to Buchan ''et al.'', the contributions a mutation makes to a "variant's attributes is not entirely understood, and there is no definitive evidence that directly links a given mutation to poor outcomes, significantly reduced efficacy of SARS-CoV-2 therapies, or vaccine coverage."<ref name="BuchanSARS21" />

			That said, and leaving the public health element to the side, if you are a laboratory conducting clinical analyses of SARS-CoV-2 specimens, the likelihood of including viral sequencing and sequence analysis for variant testing may be low for your facility. Such testing is a multi-step process requiring a non-trivial set of resources, often available to large commercial diagnostic laboratories.<ref name="BuchanSARS21" /><ref name="WilliamsEnhanc21">{{cite web \|url=https://health.mo.gov/emergencies/ert/alertsadvisories/pdf/update21921.pdf \|format=PDF \|title=Enhancing Public Health Surveillance for Variant SARSCoV-2 Viruses in Missouri \|author=Williams, R.W. \|publisher=Missouri Department of Health & Senior Services \|date=19 February 2021 \|accessdate=18 September 2021}}</ref> The CDC represents one possible workflow for genomic sequencing as such<ref name="CDCRole21">{{cite web \|url=https://www.cdc.gov/coronavirus/2019-ncov/variants/cdc-role-surveillance.html \|title=CDC’s Role in Tracking Variants \|author=Centers for Disease Control and Prevention \|publisher=Centers for Disease Control and Prevention \|date=08 September 2021 \|accessdate=18 September 2021}}</ref>:

			# A specimen containing the SARS-CoV-2 virus is received by the lab and promptly entered into the [[laboratory information system]] (LIS).
			# The RNA of the SARS-CoV-2 virus is extracted from the sample and then converted to complimentary DNA. It is then enriched and loaded into the appropriate NGS instrument.
			# The instrument runs the sequencing and raw data is collected, with the lab maintaining quality control steps. The raw data is turned into actionable sequence data.
			# The sequence data is verified for suitability, with a resequencing occurring if found to be inadequate. Otherwise, the data is then analyzed and interpreted.

			If your diagnostic lab has or is planning on adding sequencing tools to supplement clinical diagnostics, it may make sense to consider adding variant testing to your available options. But in reality, this sort of testing may largely be left to large institutions, such as the University of Rochester Vaccine Treatment Evaluation Unit or the Yale School of Public Health.<ref name="DupuyCOVID21">{{cite web \|url=https://apnews.com/article/fact-checking-549965482111 \|title=COVID-19 variants tested through genome sequencing \|author=Dupuy, B. \|work=Reuters Fact-Checking \|date=28 July 2021 \|accessdate=18 September 2021}}</ref>

← Older revision		Revision as of 16:57, 24 September 2021
Line 63:		Line 63:
	By July 2000, the LabLynx division of ASC separated to become its own incorporated entity.<ref name="SoS_llx" /> And while ASC eventually ceased to exist in 2005,<ref name="SoS_asc" /> LabLynx, Inc. went on to diversify its offerings. LabLynx’s browser-based LIMS previously demonstrated at Pittcon in 1997 expanded to become ELab, which in 2001 took on an application service provider (ASP) model of distribution.<ref name="LS_prod2">{{cite web \|url=http://www.limsource.com/products/vatlanta.html \|archiveurl= http://web.archive.org/web/20010409200118/http://www.limsource.com/products/vatlanta.html \|archivedate=9 April 2001 \|title=LIMSource: LIMS Vendor: Atlanta Systems Consultants, Inc. \|accessdate=22 October 2011}}</ref> In 2004 LabLynx released a browser-based tool called openLIMS, which gave consultants and end-users the ability "to build custom LIMS solutions that are geared to the exact operational needs of many different laboratories."<ref>{{cite web \|url=http://www.laboratorytalk.com/news/lbl/lbl100.html \|archiveurl=https://web.archive.org/web/20120419143618/http://www.laboratorytalk.com/news/lbl/lbl100.html \|title=Build your own LIMS: News from LabLynx \|work=LaboratoryTalk.com \|publisher=Pro-Talk Ltd \|date=6 January 2004 \|accessdate=29 December 2015 \|archivedate=19 April 2012}}</ref>		By July 2000, the LabLynx division of ASC separated to become its own incorporated entity.<ref name="SoS_llx" /> And while ASC eventually ceased to exist in 2005,<ref name="SoS_asc" /> LabLynx, Inc. went on to diversify its offerings. LabLynx’s browser-based LIMS previously demonstrated at Pittcon in 1997 expanded to become ELab, which in 2001 took on an application service provider (ASP) model of distribution.<ref name="LS_prod2">{{cite web \|url=http://www.limsource.com/products/vatlanta.html \|archiveurl= http://web.archive.org/web/20010409200118/http://www.limsource.com/products/vatlanta.html \|archivedate=9 April 2001 \|title=LIMSource: LIMS Vendor: Atlanta Systems Consultants, Inc. \|accessdate=22 October 2011}}</ref> In 2004 LabLynx released a browser-based tool called openLIMS, which gave consultants and end-users the ability "to build custom LIMS solutions that are geared to the exact operational needs of many different laboratories."<ref>{{cite web \|url=http://www.laboratorytalk.com/news/lbl/lbl100.html \|archiveurl=https://web.archive.org/web/20120419143618/http://www.laboratorytalk.com/news/lbl/lbl100.html \|title=Build your own LIMS: News from LabLynx \|work=LaboratoryTalk.com \|publisher=Pro-Talk Ltd \|date=6 January 2004 \|accessdate=29 December 2015 \|archivedate=19 April 2012}}</ref>

	On June 19, 2006, LabLynx established the Laboratory Informatics Institute, an open membership group with the purpose of advancing the field of laboratory informatics and shaping the standards associated with it.<ref name="LII">{{cite web \|title=Laboratory Informatics Institute Established \|url=http://www.limsfinder.com/BlogDetail.aspx?id=31049_0_3_0_C \|archiveurl=https://web.archive.org/web/20161027121044/http://www.limsfinder.com/BlogDetail.aspx?id=31049_0_3_0_C \|publisher=Laboratory Informatics Institute, Inc. \|date=17 July 2006 \|archivedate=27 October 2016 \|accessdate=26 January 2018}}</ref> LabLynx made further moves to better its LIMS offerings in August 2008, renewing and expanding its contract with Nagarro, Inc., a U.S.-based technology consulting firm. The collaboration allowed LabLynx to upgrade its existing LIMS software to .NET architecture and expand its initiative to create and market a SaaS-based LIMS.<ref name="Nagarro1">{{cite web \|url=http://www.nagarro.com/NewsEvents/Press%20Releases/LABLynx%20Extends%20Contract%20with.aspx \|archiveurl=https://web.archive.org/web/20120716033503/http://nagarro.com/NewsEvents/Press%20Releases/LABLynx%20Extends%20Contract%20with.aspx \|title=LABLynx Extends Contract with Nagarro to Include Additional Product Development and SaaS Projects \|publisher=Nagarro, Inc \|date=20 August 2008 \|accessdate=29 December 2015 \|archivedate=16 July 2012}}</ref> Less than a year after the announced renewed partnership, LabLynx revealed its redeveloped webLIMS product to the public, featuring ELab in a SaaS model and additional integration of developer tools to allow users to create and modify modules for the LIMS.<ref name="webLIMS1">{{cite web \|title=LabLynx launches the new webLiMS.com, Laboratory SaaS Provider \|url=http://scienceandresearch.argylenews.com/press_release.aspx?LabLynx-launches-the-new-webLiMScom-Laboratory-SaaS-Provider-542 \|archiveurl=https://web.archive.org/web/20160304101223/http://scienceandresearch.argylenews.com/press_release.aspx?LabLynx-launches-the-new-webLiMScom-Laboratory-SaaS-Provider-542 \|publisher=Argyle News \|date=6 March 2009 \|archivedate=04 March 2016 \|accessdate=26 January 2018}}</ref><ref name="webLIMS2">{{cite web \|title=Weblims – LabLynx \|url=https://www.scientific-computing.com/press-releases/weblims \|publisher=Scientific Computing World \|date=6 March 2009 \|accessdate=26 January 2018}}</ref> This move to a cloud-based SaaS model brought renewed interest in the company’s LIMS, with clients like the Georgia Department of Agriculture<ref name="ChemEng1">{{cite web \|url=~~http~~://cen.acs.org/articles/88/i21/LIMS-Cloud.html \|title=LIMS In The Cloud \|author=Mullin, Rick \|work=Chemical & Engineering News \|publisher=American Chemical Society \|date=24 May 2010 \|accessdate=~~29 December 2015~~}}</ref> and Cypress Bioscience<ref>{{cite web \|url=~~http~~://www.pharmaceuticalonline.com/doc/saas-model-turns-lims-paradigm-on-its-0001 \|title=SaaS Model Turns LIMS Paradigm On Its Head \|author=Dubin, Cindy \|publisher=VertMarkets, Inc \|work=Pharmaceutical Online \|date=29 July 2010 \|accessdate=~~29 December 2015~~}}</ref><ref>{{cite web \|title=SaaS - Is a web hosted LIMS right for your laboratory? \|url=http://www.lablynx.com/ArticlesBlogs/tabid/326/articleType/ArticleView/articleId/13/SaaS--Is-a-web-hosted-LIMS-right-for-your-laboratory.aspx \|archiveurl=https://web.archive.org/web/20120509064611/http://www.lablynx.com/ArticlesBlogs/tabid/326/articleType/ArticleView/articleId/13/SaaS--Is-a-web-hosted-LIMS-right-for-your-laboratory.aspx \|publisher=LabLynx, Inc \|date=15 August 2009 \|accessdate=29 December 2015 \|archivedate=09 May 2012}}</ref> taking on the new LIMS.		On June 19, 2006, LabLynx established the Laboratory Informatics Institute, an open membership group with the purpose of advancing the field of laboratory informatics and shaping the standards associated with it.<ref name="LII">{{cite web \|title=Laboratory Informatics Institute Established \|url=http://www.limsfinder.com/BlogDetail.aspx?id=31049_0_3_0_C \|archiveurl=https://web.archive.org/web/20161027121044/http://www.limsfinder.com/BlogDetail.aspx?id=31049_0_3_0_C \|publisher=Laboratory Informatics Institute, Inc. \|date=17 July 2006 \|archivedate=27 October 2016 \|accessdate=26 January 2018}}</ref> LabLynx made further moves to better its LIMS offerings in August 2008, renewing and expanding its contract with Nagarro, Inc., a U.S.-based technology consulting firm. The collaboration allowed LabLynx to upgrade its existing LIMS software to .NET architecture and expand its initiative to create and market a SaaS-based LIMS.<ref name="Nagarro1">{{cite web \|url=http://www.nagarro.com/NewsEvents/Press%20Releases/LABLynx%20Extends%20Contract%20with.aspx \|archiveurl=https://web.archive.org/web/20120716033503/http://nagarro.com/NewsEvents/Press%20Releases/LABLynx%20Extends%20Contract%20with.aspx \|title=LABLynx Extends Contract with Nagarro to Include Additional Product Development and SaaS Projects \|publisher=Nagarro, Inc \|date=20 August 2008 \|accessdate=29 December 2015 \|archivedate=16 July 2012}}</ref> Less than a year after the announced renewed partnership, LabLynx revealed its redeveloped webLIMS product to the public, featuring ELab in a SaaS model and additional integration of developer tools to allow users to create and modify modules for the LIMS.<ref name="webLIMS1">{{cite web \|title=LabLynx launches the new webLiMS.com, Laboratory SaaS Provider \|url=http://scienceandresearch.argylenews.com/press_release.aspx?LabLynx-launches-the-new-webLiMScom-Laboratory-SaaS-Provider-542 \|archiveurl=https://web.archive.org/web/20160304101223/http://scienceandresearch.argylenews.com/press_release.aspx?LabLynx-launches-the-new-webLiMScom-Laboratory-SaaS-Provider-542 \|publisher=Argyle News \|date=6 March 2009 \|archivedate=04 March 2016 \|accessdate=26 January 2018}}</ref><ref name="webLIMS2">{{cite web \|title=Weblims – LabLynx \|url=https://www.scientific-computing.com/press-releases/weblims \|publisher=Scientific Computing World \|date=6 March 2009 \|accessdate=26 January 2018}}</ref> This move to a cloud-based SaaS model brought renewed interest in the company’s LIMS, with clients like the Georgia Department of Agriculture<ref name="ChemEng1">{{cite web \|url=https://cen.acs.org/articles/88/i21/LIMS-Cloud.html \|title=LIMS In The Cloud \|author=Mullin, Rick \|work=Chemical & Engineering News \|publisher=American Chemical Society \|date=24 May 2010 \|accessdate=24 September 2021}}</ref> and Cypress Bioscience<ref>{{cite web \|url=https://www.pharmaceuticalonline.com/doc/saas-model-turns-lims-paradigm-on-its-0001 \|title=SaaS Model Turns LIMS Paradigm On Its Head \|author=Dubin, Cindy \|publisher=VertMarkets, Inc \|work=Pharmaceutical Online \|date=29 July 2010 \|accessdate=24 September 2021}}</ref><ref>{{cite web \|title=SaaS - Is a web hosted LIMS right for your laboratory? \|url=http://www.lablynx.com/ArticlesBlogs/tabid/326/articleType/ArticleView/articleId/13/SaaS--Is-a-web-hosted-LIMS-right-for-your-laboratory.aspx \|archiveurl=https://web.archive.org/web/20120509064611/http://www.lablynx.com/ArticlesBlogs/tabid/326/articleType/ArticleView/articleId/13/SaaS--Is-a-web-hosted-LIMS-right-for-your-laboratory.aspx \|publisher=LabLynx, Inc \|date=15 August 2009 \|accessdate=29 December 2015 \|archivedate=09 May 2012}}</ref> taking on the new LIMS.

	In 2011, LabLynx was involved in an initiative to standardize and structure the transmission of laboratory data that first originates in a LIMS or LIS and then moves to a person's or population of people's [[electronic health record]]s.<ref>{{cite book \|title=Laboratory Results Interface (LRI) Pilots Guide \|edition= v0.9.4.093011 \|author=Clarke, Ann \| year=2011 \|pages=1–2 \|publisher=LabLynx/mdDigest \|url=http://wiki.siframework.org/file/view/LRI_Pilots_Guide_Draft_v0_9_4_093011.docx \|archiveurl=https://web.archive.org/web/20140812142427/http://wiki.siframework.org/file/view/LRI_Pilots_Guide_Draft_v0_9_4_093011.docx \|archivedate=12 August 2014}}</ref> This laboratory results interface (LRI) pilot began in August 2011 and included collaborations with the supported open source project mdDigest and the U.S. Office of the National Coordinator for Health Information Technology (ONC).<ref>{{cite web \|title=PROJECT BRIEF: LabLynx/mdDigest Pilot \|url=http://wiki.siframework.org/LabLynx+Pilot+Brief \|archiveurl=https://web.archive.org/web/20140812142106/http://wiki.siframework.org/LabLynx+Pilot+Brief \|publisher= LabLynx/mdDigest \|archivedate=12 August 2016 \|accessdate=16 January 2018}}</ref>		In 2011, LabLynx was involved in an initiative to standardize and structure the transmission of laboratory data that first originates in a LIMS or LIS and then moves to a person's or population of people's [[electronic health record]]s.<ref>{{cite book \|title=Laboratory Results Interface (LRI) Pilots Guide \|edition= v0.9.4.093011 \|author=Clarke, Ann \| year=2011 \|pages=1–2 \|publisher=LabLynx/mdDigest \|url=http://wiki.siframework.org/file/view/LRI_Pilots_Guide_Draft_v0_9_4_093011.docx \|archiveurl=https://web.archive.org/web/20140812142427/http://wiki.siframework.org/file/view/LRI_Pilots_Guide_Draft_v0_9_4_093011.docx \|archivedate=12 August 2014}}</ref> This laboratory results interface (LRI) pilot began in August 2011 and included collaborations with the supported open source project mdDigest and the U.S. Office of the National Coordinator for Health Information Technology (ONC).<ref>{{cite web \|title=PROJECT BRIEF: LabLynx/mdDigest Pilot \|url=http://wiki.siframework.org/LabLynx+Pilot+Brief \|archiveurl=https://web.archive.org/web/20140812142106/http://wiki.siframework.org/LabLynx+Pilot+Brief \|publisher= LabLynx/mdDigest \|archivedate=12 August 2016 \|accessdate=16 January 2018}}</ref>

	In February 2015, LabLynx announced the introduction of HealthCloudPOL, a cloud-based [[laboratory information system]] (LIS) for the physician office laboratory (POL), making the basic starter package free to users.<ref name="HCPOL_LinkedIn">{{cite web \|url=https://www.linkedin.com/company/lablynx-inc./comments?topic=5979788253375520768&type=U&scope=209217&stype=C&a=NHFX \|title=Security, Reliability, and Regulatory Compliance: healthcloudpol.com \|author=LabLynx, Inc \|publisher=LinkedIn Corporation \|date=February 2015 \|accessdate=29 December 2015}}</ref><ref name="HCPOLArch">{{cite web \|url=http://www.healthcloudpol.com/ \|archiveurl=https://web.archive.org/web/20150314182554/www.healthcloudpol.com \|title=HealthCloudPOL — the FREE Cloud-based Physician Office LIS \|publisher=LabLynx, Inc \|archivedate=14 March 2015 \|accessdate=26 January 2018}}</ref> That product line soon after changed names, becoming sciCloud.net~~, though as of January 2018 that product line had not fully launched~~.		In February 2015, LabLynx announced the introduction of HealthCloudPOL, a cloud-based [[laboratory information system]] (LIS) for the physician office laboratory (POL), making the basic starter package free to users.<ref name="HCPOL_LinkedIn">{{cite web \|url=https://www.linkedin.com/company/lablynx-inc./comments?topic=5979788253375520768&type=U&scope=209217&stype=C&a=NHFX \|title=Security, Reliability, and Regulatory Compliance: healthcloudpol.com \|author=LabLynx, Inc \|publisher=LinkedIn Corporation \|date=February 2015 \|accessdate=29 December 2015}}</ref><ref name="HCPOLArch">{{cite web \|url=http://www.healthcloudpol.com/ \|archiveurl=https://web.archive.org/web/20150314182554/www.healthcloudpol.com \|title=HealthCloudPOL — the FREE Cloud-based Physician Office LIS \|publisher=LabLynx, Inc \|archivedate=14 March 2015 \|accessdate=26 January 2018}}</ref> That product line soon after changed names, becoming sciCloud.net.

	In the summer of 2019, LabLynx released its CannaQA LIMS software for the cannabis testing industry.<ref name="LLPWelcome19">{{cite web \|url=https://www.lablynxpress.com/index.php?title=Welcome_to_CannaQA \|title=Welcome to CannaQA \|work=LabLynx Press \|publisher=LabLynx, Inc \|date=11 July 2019 \|accessdate=02 March 2020}}</ref>		In the summer of 2019, LabLynx released its CannaQA LIMS software for the cannabis testing industry.<ref name="LLPWelcome19">{{cite web \|url=https://www.lablynxpress.com/index.php?title=Welcome_to_CannaQA \|title=Welcome to CannaQA \|work=LabLynx Press \|publisher=LabLynx, Inc \|date=11 July 2019 \|accessdate=02 March 2020}}</ref>
Line 74:		Line 74:

	===Community history===		===Community history===
	Since transitioning from Atlanta Systems Consultants, Inc. to LabLynx, Inc. in 2000, LabLynx has become increasingly active in the laboratory informatics community. Projects that LabLynx has started or been involved in within the community include:		Since transitioning from Atlanta Systems Consultants, Inc. to LabLynx, Inc. in 2000, LabLynx has become increasingly active in the laboratory informatics community. Projects that LabLynx has started or been involved in within the community over the years include:

	* the Laboratory Informatics Institute, an open trade association with the mission of educating, standardizing, and promoting the laboratory informatics industry<ref name="LII" />		* the Laboratory Informatics Institute, an open trade association with the mission of educating, standardizing, and promoting the laboratory informatics industry<ref name="LII" />
Line 81:		Line 81:
	* LIMSforum, a LinkedIn discussion group created to facilitate the exchange of ideas and technical information across the fields of laboratory, science, and [[health informatics]]<ref>{{cite web \|url=http://www.laboratorytalk.com/news/lbl/lbl103.html \|archiveurl=https://web.archive.org/web/20120419143627/http://www.laboratorytalk.com/news/lbl/lbl103.html \|title=Lablynx - latest company news \|work=LaboratoryTalk.com \|publisher=Pro-Talk Ltd \|date=25 August 2009 \|accessdate=29 December 2015 \|archivedate=19 April 2012}}</ref><ref>{{cite web \|title=LiMS forum - Laboratory Informatics Institute user's group for LIMS, Scientific & Health Informatics \|url=http://www.linkedin.com/groups?about=&gid=2069898 \|publisher=LinkedIn.com \|accessdate=22 October 2011}}</ref>; this later became a stand-alone community web portal.<ref name="LIMSForumSite">{{cite web \|url=https://www.limsforum.com/ \|title=LiMSForum \|publisher=LabLynx, Inc \|accessdate=26 January 2018}}</ref>		* LIMSforum, a LinkedIn discussion group created to facilitate the exchange of ideas and technical information across the fields of laboratory, science, and [[health informatics]]<ref>{{cite web \|url=http://www.laboratorytalk.com/news/lbl/lbl103.html \|archiveurl=https://web.archive.org/web/20120419143627/http://www.laboratorytalk.com/news/lbl/lbl103.html \|title=Lablynx - latest company news \|work=LaboratoryTalk.com \|publisher=Pro-Talk Ltd \|date=25 August 2009 \|accessdate=29 December 2015 \|archivedate=19 April 2012}}</ref><ref>{{cite web \|title=LiMS forum - Laboratory Informatics Institute user's group for LIMS, Scientific & Health Informatics \|url=http://www.linkedin.com/groups?about=&gid=2069898 \|publisher=LinkedIn.com \|accessdate=22 October 2011}}</ref>; this later became a stand-alone community web portal.<ref name="LIMSForumSite">{{cite web \|url=https://www.limsforum.com/ \|title=LiMSForum \|publisher=LabLynx, Inc \|accessdate=26 January 2018}}</ref>
	* LIMSuniversity, an open-access learning resource released by the Laboratory Informatics Institute, targeted towards laboratories and the LIMS community<ref>{{cite web \|title=LiMSuniversity.com, the on-line, Open Access, Virtual Learning Center for Laboratory Informatics users and professionals \|url=http://www.limsfinder.com/BlogDetail.aspx?id=35134_0_25_0_C \|archiveurl=https://web.archive.org/web/20170306214123/http://www.limsfinder.com/BlogDetail.aspx?id=35134_0_25_0_C \|publisher=Laboratory Informatics Institute, Inc. \|date=4 April 2011 \|archivedate=06 March 2017 \|accessdate=26 January 2018}}</ref>		* LIMSuniversity, an open-access learning resource released by the Laboratory Informatics Institute, targeted towards laboratories and the LIMS community<ref>{{cite web \|title=LiMSuniversity.com, the on-line, Open Access, Virtual Learning Center for Laboratory Informatics users and professionals \|url=http://www.limsfinder.com/BlogDetail.aspx?id=35134_0_25_0_C \|archiveurl=https://web.archive.org/web/20170306214123/http://www.limsfinder.com/BlogDetail.aspx?id=35134_0_25_0_C \|publisher=Laboratory Informatics Institute, Inc. \|date=4 April 2011 \|archivedate=06 March 2017 \|accessdate=26 January 2018}}</ref>
	* LIMSwiki, a Creative Commons-licensed wiki with the goal of bringing related informatics communities together to maintain a repository of information about the industry<ref>{{cite web\|title=LIMSwiki mission \|url=https://www.limswiki.org/index.php/LIMSwiki_mission \|date=4 June 2015 \|accessdate=26 January 2018}}</ref>		* LIMSwiki, a Creative Commons-licensed wiki with the goal of bringing related informatics communities together to maintain a repository of information about the industry<ref>{{cite web \|title=LIMSwiki mission \|url=https://www.limswiki.org/index.php/LIMSwiki_mission \|date=4 June 2015 \|accessdate=26 January 2018}}</ref>
			* CannaQAwiki, a Creative Commons-licensed wiki with the goal of providing content as it relates to analytically testing the ''Cannabis'' plant and its constituents in the laboratory, as well as the regulatory aspects that surround it<ref>{{cite web \|title=Welcome to CannaQAwiki \|url=https://www.cannaqa.wiki/index.php?title=Main_Page \|date=03 September 2021 \|accessdate=24 September 2021}}</ref>

	==Technology and products==		==Technology and products==

User:Shawndouglas/Sandbox - Revision history

Shawndouglas: Replaced content with "__TOC__ {{ombox | type = notice | style = width: 960px; | text = This is my primary sandbox page, where I play with features and..."

Shawndouglas at 20:21, 24 September 2021

Shawndouglas at 17:18, 24 September 2021

Shawndouglas at 16:57, 24 September 2021

Shawndouglas: /* Sandbox begins below */

Shawndouglas: Replaced content with "__TOC__ {{ombox | type = notice | style = width: 960px; | text = This is my primary sandbox page, where I play with features and..."

Shawndouglas at 16:20, 19 September 2021

Shawndouglas at 15:51, 19 September 2021

Shawndouglas at 00:15, 19 September 2021

Shawndouglas at 23:05, 18 September 2021

Shawndouglas: Replaced content with "
TOC
{{ombox | type = notice | style = width: 960px; | text = This is my primary sandbox page, where I play with features and..."

Shawndouglas: Replaced content with "
TOC
{{ombox | type = notice | style = width: 960px; | text = This is my primary sandbox page, where I play with features and..."